Focused On-demand Library for Gamma-aminobutyric acid receptor subunit beta-3

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for receptors.

Fig. 1. The sreening workflow of Receptor.AI

The method involves detailed molecular simulations of the receptor in its native membrane environment, with ensemble virtual screening focusing on its conformational mobility. When dealing with dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets on and between the subunits are established to address all possible mechanisms of action.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

P28472

UPID:

GBRB3_HUMAN

Alternative names:

GABA(A) receptor subunit beta-3

Alternative UPACC:

P28472; B7Z2W1; B7Z825; F5H3D2; H7BYV8; Q14352; Q96FM5

Background:

Gamma-aminobutyric acid receptor subunit beta-3, also known as GABA(A) receptor subunit beta-3, plays a crucial role in the brain's inhibitory signaling by forming ligand-gated chloride channels. This protein is essential for the development of functional inhibitory GABAergic synapses and mediates synaptic inhibition. It also functions as a histamine receptor, contributing to somatosensation and antinociception.

Therapeutic significance:

The protein is linked to diseases such as Epilepsy, childhood absence 5, and Developmental and epileptic encephalopathy 43, highlighting its importance in neurological disorders. Understanding the role of Gamma-aminobutyric acid receptor subunit beta-3 could open doors to potential therapeutic strategies for these conditions.